Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Houston, Texas 77030


PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Phase II trial to study the effectiveness of PS-341 in treating women who have metastatic breast cancer

Study summary:

PRIMARY OBJECTIVES: I. Determine the efficacy of PS-341, in terms of response rate, in women with metastatic breast cancer. SECONDARY OBJECTIVES: I. Determine the clinical activity of this drug, in terms of progression-free survival, in these women. II. Determine the toxicity profile and tolerability of this drug in these women. III. Determine the pharmacodynamics of this drug in these women. OUTLINE: Patients receive PS-341 IV over 3-5 seconds twice weekly on weeks 1 and 2. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A maximum of 12-35 patients will be accrued for this study within 9-12 months.


Inclusion Criteria: - Histologically or cytologically confirmed invasive breast cancer - Clinical and/or radiological evidence of stage IV disease - Relapsed or resistant disease within 6-12 months after completion of prior chemotherapy with doxorubicin or epirubicin and/or paclitaxel or docetaxel foradvanced disease or in the adjuvant setting - At least 1 unidimensionally measurable lesion - At least 20 mm by conventional techniques - At least 10 mm by spiral CT scan - No bone metastases as only measurable site - Pleural or peritoneal effusions not acceptable as measurable disease - No known brain metastases - Hormone receptor status: - Estrogen receptor-negative - Estrogen receptor-positive - Female - Performance status - ECOG 0-2 - Performance status - Karnofsky 60-100% - More than 12 weeks - WBC at least 3,000/mm^3 - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Bilirubin normal - AST or ALT no greater than 2.5 times upper limit of normal - Creatinine normal - Creatinine clearance at least 60 mL/min - No acute ischemia or significant conduction abnormality by EKG - No symptomatic congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia - LVEF greater than 50% - No uncontrolled concurrent illness - No psychiatric illness or social situation that would preclude study - No ongoing or active infection - No prior allergic reaction(s) to compounds of similar chemical or biologic composition to PS-341 - No other malignancy within the past 5 years except carcinoma in situ of the cervix or basal cell skin cancer - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective barrier-method contraception - See Chemotherapy - See Disease Characteristics - No more than 1 prior chemotherapy regimen for metastatic disease - High-dose regimen or bone marrow transplantation considered 1 prior regimen - At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered - Prior hormonal therapy for metastatic disease or in adjuvant setting allowed - Prior localized radiotherapy allowed if it does not influence the signal evaluable lesion - At least 4 weeks since prior radiotherapy and recovered - At least 2 weeks since prior minor surgery and recovered - At least 4 weeks since prior major surgery and recovered - No other concurrent investigational agent - No other concurrent investigational or commercial agents or therapies to treat this malignancy



Primary Contact:

Principal Investigator
Massimo Cristofanilli
M.D. Anderson Cancer Center

Backup Contact:


Location Contact:

Houston, Texas 77030
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 22, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.